跳至主要内容
临床试验/NL-OMON50399
NL-OMON50399已完成不适用

Protein intake in patients with colorectal or lung cancer during first line treatment with chemo(radio)- or immunotherapy when receiving a low volume, energy dense and high protein oral nutritional supplement: a randomized, controlled study - PROTEOS study

utricia Research0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • •1. Histologically proven CRC stage IIB, III or IV or histologically or
  • •cytologically proven NSCLC stage III or IV
  • •2. Eligible and scheduled for first line chemotherapy, concurrent
  • •chemoradiotherapy or immunotherapy treatment with a planned duration of at
  • •least 12 weeks
  • •3. Performance status Eastern Cooperative Oncology Group (ECOG) score 0 or 1
  • •4. Age >= 18 years
  • •5. Written informed consent

排除标准

  • •1. Scheduled for first line chemotherapy, concurrent chemoradiotherapy or
  • •immunotherapy treatment starting <=4 days after randomization
  • •2. Received >10 doses of radiotherapy within 2 months prior to the study
  • •3. Weight loss >10% in the last 6 months
  • •4. Body Mass Index < 20.0 kg/m2
  • •5. Life expectancy < 3 months
  • •6. Prescription of oral nutritional supplementation (ONS) before start of first
  • •line treatment based on hospital*s standard practice
  • •7. Presence of ileostoma or ileal pouch
  • •8. Contra-indications to oral feeding, high protein nutrition or to the test
  • •product (including galactosaemia) in the opinion of the investigator
  • •9. Known pregnancy or lactation
  • •10. Current alcohol or drug abuse in the opinion of the investigator
  • •11. Investigator's uncertainty about the willingness or ability of the subject
  • •to comply with the protocol requirements
  • •12. Participation in any other studies involving investigational or marketed
  • •products concomitantly or within two weeks prior to entry into the study

研究者

发起方
utricia Research

相似试验